Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in advancing a portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its pipeline includes CUE-221, a novel anti-IgE antibody with a dual mechanism of action, and CUE-401, designed to regulate inflammation and drive Treg-mediated tolerance.
The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016.
- Sector: Healthcare
- Industry: Biotechnology
- Full Time Employees: 29
- Founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro in 2014
- Headquartered in Boston, Massachusetts
- https://www.cuebiopharma.com
No comments:
Post a Comment